Anticoagulation therapy in pulmonary arterial hypertension

Satoshi Akagi, Kengo Fukushima Kusano

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Vascular thrombosis implicates in the pathogenesis of pulmonary arterial hypertension (PAH). Anticoagulation therapy (warfarin) has been recommended by many experts in the treatment of PAH. However, the long-term effectiveness of anticoagulation therapy remains controversial. Because of the various drugs, such as epoprostenol, bosentan, and sildenafil, for the treatment of PAH recently, warfarin alone is not a realistic therapy for PAH. Accordingly we reviewed the previous manuscript regarding anticoagulation therapy for PAH, and looked at the current role of anticoagulation therapy in Japan.

Original languageEnglish
Pages (from-to)2174-2178
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number11
Publication statusPublished - Nov 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Anticoagulation therapy in pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this